Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults
Sponsor: iBio, Inc.
Summary
The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.
Official title: A Phase I, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBIO-600 in Overweight or Obese Adult Participants (IBIO-600-CT001).
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-04
Completion Date
2027-05
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
IBIO-600
IBIO-600 Subcutaneous injection
Placebo
Matching placebo; subcutaneous injection
Locations (1)
Veritus Research
Bayswater, Victoria, Australia